Beginners Yoga House: November 2022

Wednesday, November 30, 2022

8 Early Signs of Ovarian Cancer

HEALTHY LIVING

Ovarian Cancer

8 Early Signs of Ovarian Cancer—Straight From Women Who've Experienced Them

Surgery

Amazon Shoppers Rely on These "Handy" Wipes for Keeping Their Body Clean While Recovering From Surgery

Food

These Are the Healthiest Takeout Options for Every Cuisine, According to Nutritionists

Wellness

The 8 Best Posture Correctors of 2022

Skin Conditions

11 Reasons Your Butt Itches—and What to Do About It

Depression

8 Ways to Cope With Seasonal Affective Disorder

Fitness

The Best Bodyweight Exercises You Can Do at Home

Digestive Health

When Does Constipation Become an Emergency?

Lung Conditions

3 Main Pneumonia Causes to Know, According to Doctors

Nutrition

7 Reasons Raspberries Are So Good for You

Unsubscribe

Health may receive compensation for some links to products and services in this email. Offers may be subject to change without notice.

This email was sent to lestyantoro14@gmail.com | Was this email forwarded to you? Subscribe here

Dotdash Meredith Corporation, 225 Liberty Street, 4th Floor, New York, NY 10281

A new hope for Alzheimer's

Email not displaying correctly? View it in your browser.

A new drug shows promise for Alzheimer's

By Alice Park

Senior Health Correspondent

Reporting on Alzheimer’s disease over past few decades has been both rewarding and heartbreaking. Hope for new treatments is often followed by disappointment when drugs don’t help patients as much as experts had hoped.

But the latest glimmer of hope is getting major headlines today. The Japanese company Eisai reported at a conference last night that its drug lecanemab helped people with mild-to-moderate Alzheimer’s disease slow their cognitive decline by 27% compared to people who took a placebo. Even better, the effect increased over time.

It's not an enormous improvement, but it's better than anything currently available. Here are the three most important things to know:

Lecanemab works by targeting amyloid, a protein that builds up in the brain during Alzheimer’s and eventually damages neurons. Other amyloid-based drugs—including the only approved treatment for the disease, aducanumab (or Aduhelm)—haven't been very effective. At the same conference, Roche reported that its anti-amyloid compound did not reduce amyloid enough to slow down progression of Alzheimer’s to a significant extent.
The drug comes with potential side effects, including inflammation in the brain and bleeding for those also taking anticoagulant drugs. Doctors say the inflammation is manageable if patients are monitored carefully and that the bleeding risk needs further study.
Eisai has filed for accelerated approval of the drug, and the U.S. Food and Drug Administration is expected to make a decision by early January.

READ THE STORY.

Share the story

What else to read

Many Asthma Patients Don't Follow Their Medication Plans. Here's How to Change That

By Markham Heid

A look at the latest measures to improve adherence, including new technologies and refinements to provider-patient interactions.

How Israel Became the Global Center For Alternative Meat Tech

By Aryn Baker / Tel Aviv, Israel

Israel has become the center of lab-grown meat and alternative protein technologies, thanks to its geopolitics, climate, and culture.

How the Pandemic Affected U.S. Birth Rates—and What Comes Next

By Melissa S. Kearney and Phillip Levine

At first there was a bust, then there was a boom, and now U.S. birth rates are back on their long-term, downward trend.

Air Pollution Is Linked to Stillbirths—Especially in Poorer Countries

By Jeffrey Kluger

A new study finds a connection between fine-particle air pollution and the rate of stillbirths in low- and middle-income countries.

Why Zumba Is Insanely Good Exercise

By Markham Heid

It's a party and a workout. (Originally published in 2017.)

One Last Read

The Dark Side of Hospice

In theory, hospice care is unquestionably a good thing for society: dying with dignity, in as much comfort as possible, and with the ability to spend meaningful time with loved ones in one’s own home is surely better than languishing in the clinical setting of a hospital bed.

But, as Ava Kofman writes in this deeply reported New Yorker story, it has become yet another part of the U.S. health care system that profiteers are exploiting for their own gain, with disregard to the patients (and their families) it was designed to help.

If you were forwarded this and want to sign up to receive it daily, click here.

Today's newsletter was written by Alice Park and Elijah Wolfson and edited by Mandy Oaklander.

Welcome to TIME’s Health Matters newsletter

Email not displaying correctly? View it in your browser.

Welcome to TIME's Health Matters newsletter

Dear newsletter subscribers,

As the COVID-19 pandemic nears the end of its third year, we’ll be changing the approach to our Coronavirus Brief and Health newsletters in order to deliver the most crucial information for our readers. Starting today, we’ll be sending a single daily newsletter covering the most important news, trends, and ideas across the full health and wellness spectrum. We think you’ll like the new version, but of course, you can always unsubscribe by clicking here.

For daily COVID-19 news and analysis, we encourage you to bookmark this page on our site, where we collate all of our pandemic coverage. Our goal remains to offer whatever tools we can for you to navigate a continually complex, trying time. Thanks for reading, for your feedback, and for your ongoing support.

All the best,

Elijah Wolfson (Editorial Director—Health, Climate, and Science)

Mandy Oaklander (Senior Editor—Health)